Bothell-based company Athira Pharma recently presented biomarker data from the Phase I ACT-AD study at the 15th Clinical Trials on Alzheimer’s Disease conference.
According to the results, fosgonimeton, Athira’s experimental drug, reduced levels of biomarkers for neurodegeneration (NfL) and neuroinflammation (GFAP) in patients who weren’t using acetylcholinesterase inhibitors compared to a placebo.
Fosgonimeton is intended to influence neurodegeneration and repair brain tissue by enhancing the activity of hepatocyte growth factor and its receptor, MET. The company plans to enroll 150 more patients in the trial and anticipates full enrollment of the Phase II/III trial in mid 2023 and topline results coming in early 2024.
“The bottom line is we can conclude that clinical endpoints are highly correlated to biomarkers of neurodegeneration and neuroinflammation,” said Hans J. Moebius, chief medical officer at Athira. “It’s neuroprotective and it is improving blood-based biomarkers and the clinical outcomes.”